Satellos Bioscience Inc. (MSLE) vs MetaVia Inc. (MTVA)
A side-by-side comparison of Satellos Bioscience Inc. and MetaVia Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MSLE
Satellos Bioscience Inc.
$8.03HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT
MTVA
MetaVia Inc.
$1.46HealthcareDelayed quote: Oct 6, 2026, 12:49 PM EDT
Total return — MSLE vs MTVA
growth of $100 · dividends reinvested · last 1yMSLE +13.7% (+13.7%/yr)MTVA -81.2% (-81.2%/yr)MSLE compounded faster over this window
Log scale — wide-divergence pair
MSLE MTVA
MSLE vs MTVA: by the numbers
- •MSLE is the larger company ($10M vs $10M market cap).
Metrics side by side
Valuation
| Metric | MSLE | MTVA |
|---|---|---|
| P/B ratio | 0.17 | 1.41 |
Profitability
| Metric | MSLE | MTVA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -57.34% | -211.76% |
| ROIC | -59.35% | -215.61% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.